Daniel D. Burgess

Daniel D. Burgess, listed as board member, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Santarus Inc, Nabriva Therapeutics plc and Hollis Eden Pharmaceuticals Inc /DE/. Over a trading history stretching from 13 February 2006 to 7 January 2026, the count stands at 22 filings.

On the open market, the record shows 2 purchases worth €129k and 10 sales worth €520k. Netting one side against the other leaves €391k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 3 share grants and 6 option exercises.

Most recently, on 7 January 2026, the filings show a transaction worth €28k in Cidara Therapeutics, Inc. The clock since the last published purchase (2 August 2018) now reads 3,005 days. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.